Wang Lei, Wang Yu-Xia, Zhang De-Zhong, Fang Xiang-Jie, Sun Pei-Sheng, Xue Hui-Chao
Department of General Surgery, The First Affiliated Hospital of Xinxiang Medical University, 453100, Xinxiang, PR China.
Department of Pathophysiology, Xinxiang Medical University, 453003, Xinxiang, PR China.
Biomed Pharmacother. 2016 Mar;78:301-307. doi: 10.1016/j.biopha.2016.01.028. Epub 2016 Feb 4.
MicroRNAs are believed to influence breast cancer cell tumorgenicity by interacting with the production of tumor associated macrophages. At this stage, this hypothesis lacks sufficient empirical evidence. Our study is an investigation of the effects of let-7a on the function of human breast cancer cell lines that had undergone chemokine ligand 18 (CCL18) stimulation.
Two breast cancer cell lines MDA-MB-231 and MCF-7 were transfected with let-7a mimics with or without CCL18 simulation. The expression level of let-7a was evaluated with qRT-PCR. Our study examined cell proliferation, migration and cell cycles following let-7a treatment. The predicted target of let-7a was identified and confirmed in vitro by a dual luciferase reporter system. The associations between let-7a, CCL18 and target gene expression were evaluated using RT-PCR and the Western blotting method.
The downregulated expression level of let-7a was observed in both breast cancer cell lines. When compared to the control and CCL18 stimulation groups, cell proliferation and migration in MDA-MB-231 and MCF-7 cells were significantly inhibited by let-7a. Furthermore, the cell cycle was dramatically blocked at the G2/M phase. The luciferase reporter identified Lin28 as the direct binding target of let-7a in both breast cancer cell lines.
Upregulation of let-7a carries the potential to reverse CCL18 induced cell proliferation and migration alteration in breast cancer cells by regulating Lin28 expression. Our results provided evidence which suggests the use of let-7a as a therapeutic agent in the treatment of breast cancer.
微小RNA被认为可通过与肿瘤相关巨噬细胞的产生相互作用来影响乳腺癌细胞的致瘤性。现阶段,这一假说缺乏足够的实证依据。我们的研究旨在调查let-7a对经趋化因子配体18(CCL18)刺激的人乳腺癌细胞系功能的影响。
对两种乳腺癌细胞系MDA-MB-231和MCF-7转染let-7a模拟物,同时进行或不进行CCL18模拟。用qRT-PCR评估let-7a的表达水平。我们的研究检测了let-7a处理后的细胞增殖、迁移和细胞周期。通过双荧光素酶报告系统在体外鉴定并确认了let-7a的预测靶点。使用RT-PCR和蛋白质印迹法评估let-7a、CCL18与靶基因表达之间的关联。
在两种乳腺癌细胞系中均观察到let-7a表达水平下调。与对照组和CCL18刺激组相比,let-7a显著抑制了MDA-MB-231和MCF-7细胞的增殖和迁移。此外,细胞周期在G2/M期被显著阻断。荧光素酶报告实验确定Lin28为两种乳腺癌细胞系中let-7a的直接结合靶点。
let-7a的上调有可能通过调节Lin28表达来逆转CCL18诱导的乳腺癌细胞增殖和迁移改变。我们的结果提供了证据,表明let-7a可作为治疗乳腺癌的一种治疗剂。